United States, March 12 -- The U.S. Food and Drug Administration launched a new unified platform for analyzing adverse event reports. This platform - called the FDA Adverse Event Monitoring System (AEMS) - represents a major achievement in the agency's mission to modernize and provide radical transparency into the safety of regulated products. With the new system, adverse event reports submitted to the FDA for drugs, biologics, vaccines, cosmetics, and animal food can be displayed in a single streamlined dashboard. In the months ahead, all remaining product centers will begin processing adverse event reports in AEMS. The agency will also migrate historical adverse event data to AEMS, decommission certain legacy systems, and roll out enhance...